Literature DB >> 19521638

Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress.

Stephen J Wood1, Murat Yücel, Christos Pantelis, Michael Berk.   

Abstract

Mitochondrial dysfunction and oxidative stress are increasingly implicated in the pathophysiology of schizophrenia. The brain is the body's highest energy consumer, and the glutathione system is the brain's dominant free radical scavenger. In the current paper, we review the evidence of central and peripheral nervous system anomalies in the oxidative defences of individuals with schizophrenia, principally involving the glutathione system. This is reflected by evidence of the manifold consequences of oxidative stress that include lipid peroxidation, protein carboxylation, DNA damage and apoptosis - all potentially part of the process of neuroprogression in the disorder. Importantly, oxidative stress is amenable to intervention. We consider the clinical potential of some possible interventions that help reduce oxidative stress, via augmentation of the glutathione system, particularly N-acetyl cysteine. We argue that a better understanding of the mechanisms and pathways underlying oxidative stress will assist in developing the therapeutic potential of this area.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521638

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  35 in total

1.  Inhibition of mouse aging by using an essential oil composition.

Authors:  E B Burlakova; T A Misharina; A K Vorobyeva; E S Alinkina; L D Fatkullina; M B Terenina; N I Krikunova
Journal:  Dokl Biochem Biophys       Date:  2012-07-08       Impact factor: 0.788

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 3.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

4.  Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways.

Authors:  Yaoyang Zhang; Michaela D Filiou; Stefan Reckow; Philipp Gormanns; Giuseppina Maccarrone; Melanie S Kessler; Elisabeth Frank; Boris Hambsch; Florian Holsboer; Rainer Landgraf; Christoph W Turck
Journal:  Mol Cell Proteomics       Date:  2011-08-23       Impact factor: 5.911

5.  Effect of aspartame on oxidative stress and monoamine neurotransmitter levels in lipopolysaccharide-treated mice.

Authors:  Omar M E Abdel-Salam; Neveen A Salem; Jihan Seid Hussein
Journal:  Neurotox Res       Date:  2011-08-06       Impact factor: 3.911

6.  Insulin-like growth factor 1 and transforming growth factor-β stimulate cystine/glutamate exchange activity in dental pulp cells.

Authors:  Katherine Pauly; Kymberly Fritz; Alyssa Furey; Doug Lobner
Journal:  J Endod       Date:  2011-05-08       Impact factor: 4.171

7.  Getting a Knack for NAC: N-Acetyl-Cysteine.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2011-01

8.  Preliminary Safety Assessment of New Azinesulfonamide Analogs of Aripiprazole using Prokaryotic Models.

Authors:  Beata Powroźnik; Karolina Słoczyńska; Krzysztof Marciniec; Paweł Zajdel; Elżbieta Pękala
Journal:  Adv Pharm Bull       Date:  2016-09-25

9.  Is the PentaBDE replacement, tris (1,3-dichloro-2-propyl) phosphate (TDCPP), a developmental neurotoxicant? Studies in PC12 cells.

Authors:  Laura V Dishaw; Christina M Powers; Ian T Ryde; Simon C Roberts; Frederic J Seidler; Theodore A Slotkin; Heather M Stapleton
Journal:  Toxicol Appl Pharmacol       Date:  2011-01-19       Impact factor: 4.219

10.  Childhood adversities are associated with shorter telomere length at adult age both in individuals with an anxiety disorder and controls.

Authors:  Laura Kananen; Ida Surakka; Sami Pirkola; Jaana Suvisaari; Jouko Lönnqvist; Leena Peltonen; Samuli Ripatti; Iiris Hovatta
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.